Bristol Myers Squibb Unveils $2.3 Billion State-of-the-Art Manufacturing Campus in Houston, Texas

Bristol Myers Squibb is embarking on a transformative expansion of its pharmaceutical manufacturing operations in the United States with the establishment of a cutting-edge $2.3 billion campus in Houston, Texas. This ambitious project highlights the company’s dedication to scaling up domestic production capabilities to meet the rising demand for innovative biopharmaceutical treatments.

The new facility is designed to incorporate the latest advancements in manufacturing technology and sustainable practices, reinforcing Bristol Myers Squibb’s position as a pioneer in the biopharma sector. This expansion not only aims to enhance production volumes for both small molecule drugs and biologics but also to strengthen supply chain robustness and accelerate patient access to vital therapies.

• Expanded manufacturing output: Capacity to produce increased quantities of diverse pharmaceutical products.
• Employment growth: Creation of approximately 1,000 new jobs spanning scientific, technical, and operational roles.
• Technological innovation: Integration of digital automation and data-driven analytics to optimize manufacturing efficiency.
• Environmental responsibility: Commitment to reducing carbon emissions and conserving water resources through sustainable design.